|
1
|
Lazăr DC, Tăban S, Cornianu M, Faur A and
Goldiş A: New advances in targeted gastric cancer treatment. World
J Gastroenterol. 22:6776–6799. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yu T, Chen X, Lin T, Liu J, Li M, Zhang W,
Xu X, Zhao W, Liu M, Napier DL, et al: KLF4 deletion alters gastric
cell lineage and induces MUC2 expression. Cell Death Dis.
7:e22552016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Apicella M, Corso S and Giordano S:
Targeted therapies for gastric cancer: Failures and hopes from
clinical trials. Oncotarget. 8:57654–57669. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Molina-Castro S, Pereira-Marques J,
Figueiredo C, Machado JC and Varon C: Gastric cancer: Basic
aspects. Helicobacter. 22 Suppl 1:2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang L, Wu J, Lu J, Ma R, Sun D and Tang
J: Regulation of the cell cycle and PI3K/Akt/mTOR signaling pathway
by tanshinone I in human breast cancer cell lines. Mol Med Rep.
11:931–939. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gutheil WG, Reed G, Ray A, Anant S and
Dhar A: Crocetin: An agent derived from saffron for prevention and
therapy for cancer. Curr Pharm Biotechnol. 13:173–179. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gao H, Lamusta J, Zhang WF, Salmonsen R,
Liu Y, O'Connell E, Evans JE, Burstein S and Chen JJ: Tumor cell
selective cytotoxicity and apoptosis induction by an herbal
preparation from brucea javanica. N Am J Med Sci (Boston). 4:62–66.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wei B, You MG, Ling JJ, Wei LL, Wang K, Li
WW, Chen T, Du QM and Ji H: Regulation of antioxidant system,
lipids and fatty acid β-oxidation contributes to the
cardioprotective effect of sodium tanshinone IIA sulphonate in
isoproterenol-induced myocardial infarction in rats.
Atherosclerosis. 230:148–156. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhou L, Zuo Z and Chow MS: Danshen: An
overview of its chemistry, pharmacology, pharmacokinetics, and
clinical use. J Clin Pharmacol. 45:1345–1359. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fang J, Little PJ and Xu S:
Atheroprotective effects and molecular targets of tanshinones
derived from herbal medicine danshen. Med Res Rev. 38:201–228.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li G, Shan C, Liu L, Zhou T, Zhou J, Hu X,
Chen Y, Cui H and Gao N: Tanshinone IIA inhibits HIF-1α and VEGF
expression in breast cancer cells via mTOR/p70S6K/RPS6/4E-BP1
signaling pathway. PLoS One. 10:e01174402015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huang SY, Chang SF, Liao KF and Chiu SC:
Tanshinone IIA inhibits epithelial-mesenchymal transition in
bladder cancer cells via modulation of STAT3-CCL2 signaling. Int J
Mol Sci. 18:pii: E1616. 2017. View Article : Google Scholar
|
|
15
|
Zhang Y, Jiang P, Ye M, Kim SH, Jiang C
and Lü J: Tanshinones: Sources, pharmacokinetics and anti-cancer
activities. Int J Mol Sci. 13:13621–13666. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Su CC: Tanshinone IIA inhibits human
gastric carcinoma AGS cell growth by decreasing BiP, TCTP, Mcl1 and
BclxL and increasing Bax and CHOP protein expression. Int J Mol
Med. 34:1661–1668. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yu J, Wang X, Li Y and Tang B: Tanshinone
IIA suppresses gastric cancer cell proliferation and migration by
downregulation of FOXM1. Oncol Rep. 37:1394–1400. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yu H, Kortylewski M and Pardoll D:
Crosstalk between cancer and immune cells: Role of STAT3 in the
tumour microenvironment. Nat Rev Immunol. 7:41–51. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Grivennikov SI and Karin M: Dangerous
liaisons: STAT3 and NF-kappaB collaboration and crosstalk in
cancer. Cytokine Growth Factor Rev. 21:11–19. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Park E, Park J, Han SW, Im SA, Kim TY, Oh
DY and Bang YJ: NVP-BKM120, a novel PI3K inhibitor, shows synergism
with a STAT3 inhibitor in human gastric cancer cells harboring KRAS
mutations. Int J Oncol. 40:1259–1266. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Guo C, Su J, Li Z, Xiao R, Wen J, Li Y,
Zhang M, Zhang X, Yu D, Huang W, et al: The G-protein-coupled bile
acid receptor Gpbar1 (TGR5) suppresses gastric cancer cell
proliferation and migration through antagonizing STAT3 signaling
pathway. Oncotarget. 6:34402–34413. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang J, Chatterjee-Kishore M, Staugaitis
SM, Nguyen H, Schlessinger K, Levy DE and Stark GR: Novel roles of
unphosphorylated STAT3 in oncogenesis and transcriptional
regulation. Cancer Res. 65:939–947. 2005.PubMed/NCBI
|
|
23
|
Chen J, Wang J, Lin L, He L, Wu Y, Zhang
L, Yi Z, Chen Y, Pang X and Liu M: Inhibition of STAT3 signaling
pathway by nitidine chloride suppressed the angiogenesis and growth
of human gastric cancer. Mol Cancer Ther. 11:277–287. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xiong H, Du W, Wang JL, Wang YC, Tang JT,
Hong J and Fang JY: Constitutive activation of STAT3 is predictive
of poor prognosis in human gastric cancer. J Mol Med (Berl).
90:1037–1046. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mastoraki A, Benetou C, Mastoraki S,
Papanikolaou IS, Danias N, Smyrniotis V and Arkadopoulos N: The
role of surgery in the therapeutic approach of gastric cancer liver
metastases. Indian J Gastroenterol. 35:331–336. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jiang X, Wang W, Yang Y, Du L, Yang X,
Wang L, Zheng G, Duan W, Wang R, Zhang X, et al: Identification of
circulating microRNA signatures as potential noninvasive biomarkers
for prediction and prognosis of lymph node metastasis in gastric
cancer. Oncotarget. 8:65132–65142. 2017.PubMed/NCBI
|
|
27
|
Kagawa S, Shigeyasu K, Ishida M, Watanabe
M, Tazawa H, Nagasaka T, Shirakawa Y and Fujiwara T: Molecular
diagnosis and therapy for occult peritoneal metastasis in gastric
cancer patients. World J Gastroenterol. 20:17796–17803. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mohelnikova-Duchonova B, Melichar B and
Soucek P: FOLFOX/FOLFIRI pharmacogenetics: The call for a
personalized approach in colorectal cancer therapy. World J
Gastroenterol. 20:10316–10330. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang F, Zhang D, Mao J, Ke XX, Zhang R,
Yin C, Gao N and Cui H: Morusin inhibits cell proliferation and
tumor growth by down-regulating c-Myc in human gastric cancer.
Oncotarget. 8:57187–57200. 2017.PubMed/NCBI
|
|
30
|
Wang X, Morris-Natschke SL and Lee KH: New
developments in the chemistry and biology of the bioactive
constituents of Tanshen. Med Res Rev. 27:133–148. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dong Y, Morris-Natschke SL and Lee KH:
Biosynthesis, total syntheses, and antitumor activity of
tanshinones and their analogs as potential therapeutic agents. Nat
Prod Rep. 28:529–542. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xu M, Cao FL, Li NY, Liu YQ, Li YP and Lv
CL: Tanshinone IIA reverses the malignant phenotype of SGC7901
gastric cancer cells. Asian Pac J Cancer Prev. 14:173–177. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lin JY, Ke YM, Lai JS and Ho TF:
Tanshinone IIA enhances the effects of TRAIL by downregulating
survivin in human ovarian carcinoma cells. Phytomedicine.
22:929–938. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lee H, Herrmann A, Deng JH, Kujawski M,
Niu G, Li Z, Forman S, Jove R, Pardoll DM and Yu H: Persistently
activated Stat3 maintains constitutive NF-kappaB activity in
tumors. Cancer Cell. 15:283–293. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mora LB, Buettner R, Seigne J, Diaz J,
Ahmad N, Garcia R, Bowman T, Falcone R, Fairclough R, Cantor A, et
al: Constitutive activation of Stat3 in human prostate tumors and
cell lines: Direct inhibition of Stat3 signaling induces apoptosis
of prostate cancer cells. Cancer Res. 62:6659–6666. 2002.PubMed/NCBI
|
